Cargando…

Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors

Background: The timing of imaging for (68)gallium ((68)Ga)-PSMA and (68)Ga-DOTATOC are stated to be around 60 min post-injection (p.i.). In some lesions, late imaging (3–4 h p.i.) showed advantages. The aim of our evaluation was to demonstrate the relevance of an “early” late acquisition. Methods: W...

Descripción completa

Detalles Bibliográficos
Autores principales: Librizzi, Damiano, Eilsberger, Friederike, Ottenthaler, Stefan, Ebrahimifard, Ali, Luster, Markus, Yousefi, Behrooz H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136247/
https://www.ncbi.nlm.nih.gov/pubmed/37189670
http://dx.doi.org/10.3390/biomedicines11041052
_version_ 1785032171956731904
author Librizzi, Damiano
Eilsberger, Friederike
Ottenthaler, Stefan
Ebrahimifard, Ali
Luster, Markus
Yousefi, Behrooz H.
author_facet Librizzi, Damiano
Eilsberger, Friederike
Ottenthaler, Stefan
Ebrahimifard, Ali
Luster, Markus
Yousefi, Behrooz H.
author_sort Librizzi, Damiano
collection PubMed
description Background: The timing of imaging for (68)gallium ((68)Ga)-PSMA and (68)Ga-DOTATOC are stated to be around 60 min post-injection (p.i.). In some lesions, late imaging (3–4 h p.i.) showed advantages. The aim of our evaluation was to demonstrate the relevance of an “early” late acquisition. Methods: We retrospectively evaluated 112 patients who underwent (68)Ga-DOTATOC-PET/CT and 82 patients who underwent (68)Ga-PSMA-PET/CT. The first scan was acquired 60 min (±15 min) after application. In cases of diagnostic ambiguity, a second scan was performed 30–60 min later. Pathological lesions were analyzed. Results: Almost half of all (68)Ga-DOTATOC cases and about one-third of all (68)Ga-PSMA examinations showed a change in findings due to the second acquisition. In total, 45.5% of neuroendocrine tumor (NET) patients and 66.7% of prostate cancer (PCa) patients showed relevant TNM classification changes. For (68)Ga-PSMA, there were significant increases in sensitivity and specificity from 81.8% to 95.7% and from 66.7% to 100%, respectively. Statistically significant improvements in sensitivity (from 53.3% to 93.3%) and specificity (from 54.6% to 86.4%) were demonstrated for NET patients. Conclusion: Early second images can improve diagnostics with (68)Ga-DOTATOC and (68)Ga-PSMA PET/CT.
format Online
Article
Text
id pubmed-10136247
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-101362472023-04-28 Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors Librizzi, Damiano Eilsberger, Friederike Ottenthaler, Stefan Ebrahimifard, Ali Luster, Markus Yousefi, Behrooz H. Biomedicines Article Background: The timing of imaging for (68)gallium ((68)Ga)-PSMA and (68)Ga-DOTATOC are stated to be around 60 min post-injection (p.i.). In some lesions, late imaging (3–4 h p.i.) showed advantages. The aim of our evaluation was to demonstrate the relevance of an “early” late acquisition. Methods: We retrospectively evaluated 112 patients who underwent (68)Ga-DOTATOC-PET/CT and 82 patients who underwent (68)Ga-PSMA-PET/CT. The first scan was acquired 60 min (±15 min) after application. In cases of diagnostic ambiguity, a second scan was performed 30–60 min later. Pathological lesions were analyzed. Results: Almost half of all (68)Ga-DOTATOC cases and about one-third of all (68)Ga-PSMA examinations showed a change in findings due to the second acquisition. In total, 45.5% of neuroendocrine tumor (NET) patients and 66.7% of prostate cancer (PCa) patients showed relevant TNM classification changes. For (68)Ga-PSMA, there were significant increases in sensitivity and specificity from 81.8% to 95.7% and from 66.7% to 100%, respectively. Statistically significant improvements in sensitivity (from 53.3% to 93.3%) and specificity (from 54.6% to 86.4%) were demonstrated for NET patients. Conclusion: Early second images can improve diagnostics with (68)Ga-DOTATOC and (68)Ga-PSMA PET/CT. MDPI 2023-03-29 /pmc/articles/PMC10136247/ /pubmed/37189670 http://dx.doi.org/10.3390/biomedicines11041052 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Librizzi, Damiano
Eilsberger, Friederike
Ottenthaler, Stefan
Ebrahimifard, Ali
Luster, Markus
Yousefi, Behrooz H.
Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors
title Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors
title_full Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors
title_fullStr Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors
title_full_unstemmed Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors
title_short Diagnostic Impact of Dual-Time PET/CT with (68)Gallium-PSMA in Prostate Cancer and (68)Gallium-DOTATOC in Neuroendocrine Tumors
title_sort diagnostic impact of dual-time pet/ct with (68)gallium-psma in prostate cancer and (68)gallium-dotatoc in neuroendocrine tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10136247/
https://www.ncbi.nlm.nih.gov/pubmed/37189670
http://dx.doi.org/10.3390/biomedicines11041052
work_keys_str_mv AT librizzidamiano diagnosticimpactofdualtimepetctwith68galliumpsmainprostatecancerand68galliumdotatocinneuroendocrinetumors
AT eilsbergerfriederike diagnosticimpactofdualtimepetctwith68galliumpsmainprostatecancerand68galliumdotatocinneuroendocrinetumors
AT ottenthalerstefan diagnosticimpactofdualtimepetctwith68galliumpsmainprostatecancerand68galliumdotatocinneuroendocrinetumors
AT ebrahimifardali diagnosticimpactofdualtimepetctwith68galliumpsmainprostatecancerand68galliumdotatocinneuroendocrinetumors
AT lustermarkus diagnosticimpactofdualtimepetctwith68galliumpsmainprostatecancerand68galliumdotatocinneuroendocrinetumors
AT yousefibehroozh diagnosticimpactofdualtimepetctwith68galliumpsmainprostatecancerand68galliumdotatocinneuroendocrinetumors